NCT00050440 - Phase 2 Study of ET-743 (Trabectedin) in Patients With Persistent or Recurrent Endometrial Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2002

Study Completion Date

July 31, 2004

Conditions

Endometrial NeoplasmsUterine NeoplasmsGenital Neoplasms, Female Urogenital Neoplasms

Interventions

DRUG

Trabectedin

Trabectedin 1.3 mg/m2 administered intravenously every 21 days.

DRUG

Dexamethasone

Dexamethasone 4 mg administered orally (by mouth) the day before the trabectedin dose, 30 minutes before the trabectedin dose, and for 2 days following the trabectedin dose

Trial Locations (14)

Unknown

Los Angeles

Miami

Lexington

Baltimore

New York

Oklahoma City

Nashville

Dallas

Toronto

Maastricht

Moscow

Obninsk

Saint Petersburg

Saint